# Cencora share price today (Cencora, Inc., COR)

> Cencora, Inc.'s earnings have grown faster than its share price. Earnings per share grew +5.7% in a year while the price moved +0.8%. COR · Healthcare · Medical Distribution · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/cor

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting better, from the last 12 quarters
- Price: $340.50 (+0.8% in a year)
- P/E: 25.3× (higher than 58% of the last 4.6 years)
- Revenue (Jun 2026): $84.8 B (+5.1% on a year ago)
- Profit (Jun 2026): $764 M (+11.1% on a year ago)
- Operating margin: 1.4% (+0.2 points on a year ago)
- ROE: 89%, FY25
- ROIC: 20.9%, against a 6.5% cost of capital: +14.4 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Cencora share price today? Cencora, Inc.'s share price was $340.50 at the close on 3 November 2026. It has been stalling near its high for 5 weeks. That is 7.4% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 14 weeks in a row. In the last 52 weeks it traded between $258 and $372, and at that close it sat 72% of the way up from that low. Over the last 10 years the share price moved +316% while the S&P 500 moved +255%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Cencora pay? Cencora, Inc. paid $2.35 per share over the last four reported quarters. The most recent declaration was $0.60 for Jun 2026. At today's price of $340.50 that is a yield of 0.69%, based on dividends already paid, not a forecast. ## Which stock lists is Cencora on? Cencora is on one of our US lists: S&P 500 companies. [S&P 500 companies](https://www.sectoralpha.in/sp-500-stocks)

## Is Cencora profitable? Cencora, Inc. earned $764 M of net profit in the Jun 2026 quarter, +11.1% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY25 profit was $1.6 B. Over 4 years profit has grown 0.2% a year on average. That is 0.9% of the quarter's revenue. The same quarter a year earlier earned $687 M. 1 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $1.6 B (+3.0% on the year before). Why profit moved: revenue changed +5.1% on a year earlier and the margin moved +0.2 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed −2,497.6% and revenue +5.1%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Cencora make, and is it growing? Cencora, Inc. reported $84.8 B of revenue in the Jun 2026 quarter, +5.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 10.7% a year on average. The last full year, FY25, came in at $321 B. The last four reported quarters add to $333 B. FY25 revenue was $321 B, +9.3% on the year before. Recent pace: the last four quarters grew +5.1% on average, against 10.7% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +5.1%, against +8.3% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +38.3%, against +18.9% a year (accelerating). ## How much of every $100 of sales does Cencora keep? Cencora, Inc.'s operating margin was 1.4% in the Jun 2026 quarter, 0.2 percentage points higher than the same quarter a year ago. Across 5 years it has been between 0.9% and 1.3%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +0.2 percentage points on the year while gross margin changed +0.6 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Cencora's profit turning into cash? Over the last 3 years, 234% of Cencora, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $3.9 B of operating cash against $1.6 B of profit. After $668 M of spending on assets, $3.2 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Cencora's cash go? Cencora, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.6 B on assets over the last 3 years. Averaged over those years that is 0.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.6 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Cencora's P/E ratio, and how does it compare with its own history? Cencora, Inc.'s P/E is 25.3×, in the middle of its own history: higher than 58% of past readings. Its usual P/E (the middle reading) is 24.1×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +5.7% while the price moved +0.8%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved +20.4% a year; about +16.4% a year came from earnings growth and about +4.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Cencora business getting better or worse? Cencora, Inc.'s business is getting better. Profit growth hit its low 6 quarters ago at −13.5% and has recovered to +38.3%, with ROCE rising at 23.2%. This is based on 12 quarters of 4 measures. Why it matters: a lasting rise from a low is what this page is built to show. ## How much does Cencora earn on its capital? Cencora, Inc. earned a ROE of 89% in FY25. Its return on capital used (ROIC) is 14.4 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 0.5% net margin and 4.20× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 0.5% net margin × 4.20× asset turnover × 43.84× leverage (assets divided by equity) ≈ 92.1% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 20.9% − 6.5% = +14.4 percentage points. The 6.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 20.9% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 51.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Cencora have too much debt? Cencora, Inc. has total debt of $14.5 B against shareholder equity of $3.2 B as of Jun 2026, so its debt is 4.47× its equity. Year by year, that ratio went from 13.36 in FY21 to 5.34 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Cencora shareholding pattern? 2.2% of Cencora, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Cencora from balance-sheet trouble? For Cencora, Inc., the Z-score is 4.70. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 4.70 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Cencora rank in its industry? 63.6 out of 100, rank 2 of 8 in Medical Distribution, with 85% of the evidence available. Cencora, Inc. scores 63.6 out of 100 against the 8 companies it is compared with in Medical Distribution, ranking 2. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 19.7 + 14.9 + 15.5 + 13.5 = 63.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Cencora compared with? Cencora ranks 2 of 8 Medical Distribution companies on the 4-Factor Sector Score, with 63.6 out of 100. 1. [McKesson Corporation](https://www.sectoralpha.in/us/stocks/mck) MCK · leader · Most evidence points up · 85% evidence 79.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.7/35 · Revenue 8.8% · Profit 58.1% · Operating margin change 0 points · 95% evidence Capital efficiency 18.2/25 · ROCE 36.7% · Operating margin 1.3% · 76% evidence Valuation 16.0/20 · P/E 19.3× · PEG 0.39 · 65% evidence Relative strength 20.0/20 · Lead over its industry 12% · Lead over S&P 500 10.5% · 1 year 17.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25.7 + 18.2 + 16 + 20 = 79.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. Cencora, Inc. this page COR · breaking out · Evidence leans up · 85% evidence 63.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 5.1% · Profit 38.4% · Operating margin change 0.2 points · 95% evidence Capital efficiency 14.9/25 · ROCE 18.3% · Operating margin 1.4% · 76% evidence Valuation 15.5/20 · P/E 21× · PEG 0.54 · 65% evidence Relative strength 13.5/20 · Lead over its industry 1.3% · Lead over S&P 500 -0.1% · 1 year -5.6% · 100% evidence · 8 of 12 weeks ahead Exact sum: 19.7 + 14.9 + 15.5 + 13.5 = 63.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Cardinal Health, Inc.](https://www.sectoralpha.in/us/stocks/cah) CAH · turning · Evidence leans up · 85% evidence 58.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue 14.2% · Profit 9.8% · Operating margin change 0.2 points · 95% evidence Capital efficiency 15.9/25 · ROCE 24.5% · Operating margin 1.3% · 76% evidence Valuation 5.0/20 · P/E 32.5× · PEG 2.72 · 65% evidence Relative strength 16.6/20 · Lead over its industry 11.2% · Lead over S&P 500 9.8% · 1 year 24.2% · 100% evidence · 7 of 12 weeks ahead Exact sum: 20.9 + 15.9 + 5 + 16.6 = 58.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Henry Schein, Inc.](https://www.sectoralpha.in/us/stocks/hsic) HSIC · quiet · Evidence leans down · 85% evidence 41.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6.5% · Profit 6% · Operating margin change 0.4 points · 95% evidence Capital efficiency 12.6/25 · ROCE 9.9% · Operating margin 5.8% · 76% evidence Valuation 7.3/20 · P/E 24× · PEG 2.33 · 65% evidence Relative strength 7.4/20 · Lead over its industry -0.6% · Lead over S&P 500 -1.8% · 1 year 14.7% · 100% evidence · 4 of 12 weeks ahead Exact sum: 14.6 + 12.6 + 7.3 + 7.4 = 41.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Akso Health Group](https://www.sectoralpha.in/us/stocks/ahg) AHG · basing · Too little evidence to rank firmly · 51% evidence 35.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.2/35 · Revenue n/a · Profit n/a · Operating margin change 5.6 points · 26% evidence Capital efficiency 4.8/25 · ROCE -2.2% · Operating margin -37.5% · 76% evidence Valuation 9.5/20 · P/E 25.6× · PEG n/a · 15% evidence Relative strength 3.7/20 · Lead over its industry -20.9% · Lead over S&P 500 -23.3% · 1 year -22.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 17.2 + 4.8 + 9.5 + 3.7 = 35.2 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 6. EDAP TMS S.A. FOCL · quiet · Most evidence points down · 67% evidence 28.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.2/35 · Revenue 7.1% · Profit n/a · Operating margin change 8.8 points · 71% evidence Capital efficiency 3.0/25 · ROCE -71.4% · Operating margin -60.8% · 76% evidence Valuation 8.5/20 · P/E 71.3× · PEG n/a · 15% evidence Relative strength 2.7/20 · Lead over its industry -2.6% · Lead over S&P 500 -4.3% · 1 year 103.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 14.2 + 3 + 8.5 + 2.7 = 28.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. Empro Group Inc. EMPG · Too little evidence to rank firmly · 16% evidence 56.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.7/43.75 · Revenue n/a · Profit n/a · Operating margin change 65.6 points · 5% evidence Capital efficiency 21.6/31.25 · ROCE 39.6% · Operating margin 36.1% · 57% evidence Valuation 12.5/25 · P/E n/a · PEG n/a · 0% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 22.7 + 21.6 + 12.5 = 56.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 8. Accendra Health, Inc. ACH · Too little evidence to rank firmly · 38% evidence 36.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.7/43.75 · Revenue n/a · Profit n/a · Operating margin change -8.7 points · 45% evidence Capital efficiency 8.6/31.25 · ROCE 4.3% · Operating margin -1.5% · 76% evidence Valuation 14.4/25 · P/E -35.7× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 13.7 + 8.6 + 14.4 = 36.7 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Distribution](https://www.sectoralpha.in/us/sectors/medical-distribution), all 8 compared on one page. ## Which companies are close to Cencora in size? Cencora is the 2nd largest of 6 Medical Distribution companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: McKesson Corporation. Just below it: Cardinal Health, Inc., Henry Schein, Inc., Akso Health Group and EDAP TMS S.A. ### Medical Distribution companies close in size

1. [McKesson Corporation](https://www.sectoralpha.in/us/stocks/mck) $116.5 billion
2. Cencora, Inc. $65 billion
3. [Cardinal Health, Inc.](https://www.sectoralpha.in/us/stocks/cah) $58.6 billion
4. [Henry Schein, Inc.](https://www.sectoralpha.in/us/stocks/hsic) $9.2 billion
5. [Akso Health Group](https://www.sectoralpha.in/us/stocks/ahg) $1 billion
6. [EDAP TMS S.A.](https://www.sectoralpha.in/us/stocks/focl) $189 million

[All 6 Medical Distribution companies, largest first](https://www.sectoralpha.in/us/sectors/medical-distribution#all-companies)

### Companies close in size in other industries

1. [NXP Semiconductors N.V.](https://www.sectoralpha.in/us/stocks/nxpi) $64.8 billion · Semiconductors
2. [Public Storage](https://www.sectoralpha.in/us/stocks/psa) $64.7 billion · REIT - Industrial
3. Cencora, Inc. $64.5 billion
4. [CRH plc](https://www.sectoralpha.in/us/stocks/crh) $64.3 billion · Building Materials
5. [Boston Scientific Corporation](https://www.sectoralpha.in/us/stocks/bsx) $64.2 billion · Medical Devices

## What else do people ask about Cencora? ### What is Cencora's stock price today? Cencora, Inc.'s stock price is $340.50, +0.8% over the past year. The whole company is worth $65.0 B on the market. In the last 52 weeks it traded between $258 to $372; today it is 72% of the way up from the low, 7.4% above its 200-day average (as of 3 November 2026). ### What were Cencora's latest quarterly results? Cencora, Inc. reported revenue of $84.8 B and net profit of $764 M for the Jun 2026 quarter. Revenue rose 5.1% and profit rose 11.1% compared with a year earlier. Earnings per share were $3.94. The operating margin was 1.4%, 0.2 percentage points higher than a year earlier (as of 3 November 2026). ### What is Cencora's market cap? Cencora, Inc.'s market capitalisation is $65.0 B at a stock price of $340.50. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Cencora performing? Cencora, Inc.'s share price has been stalling near its high for 5 weeks. In its latest quarter, revenue rose 5.1% and profit rose 11.1% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 14 weeks running (as of 3 November 2026). ### Will Cencora's stock price go up? This page does not forecast Cencora, Inc.'s stock price. What it shows instead: the stock price is $340.50, and it has been stalling near its high for 5 weeks. Its P/E of 25.3× is higher than 58% of its own last 5 years (as of 3 November 2026). ### Where is Cencora in its business cycle? Cencora, Inc.'s FY25 operating margin was 1.2%, against a 5-year range of 0.9% to 1.3%: the middle of its own range, neither a peak nor a low. The latest quarter was 1.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Cencora story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Cencora a stock worth studying right now? What the numbers show: Cencora, Inc.'s earnings have grown faster than its share price. Earnings per share grew +5.7% in a year while the price moved +0.8%. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- S&P 500 companies: https://www.sectoralpha.in/sp-500-stocks

This is research, not advice. We’re not SEBI-registered.